Mamta Kalra joined Immatics in 2016 and is responsible for the manufacturing process and analytical development of autologous and allogeneic adoptive cell therapy programs.
Mamta has over 20 years of experience in the field of basic and applied Immunology with 13+ years in the field of cell and gene therapy. She completed her doctoral research in TB vaccine development before transitioning from Infectious Disease to Cancer Immunology in her postdoctoral years. Initially she studied immunomodulatory factors in HCV-related liver cancer followed by T-cell therapy of EBV-related cancers at the Center for Cell and Gene Therapy at Baylor College of Medicine. Mamta was instrumental in the process and analytical development for multiple adoptive T-cell therapy trials, including process optimization, potency testing of products and immune-monitoring.
Upon joining Immatics, she led the process development for the ACTengine® program and gradually expanded her contributions to encompass diverse activities under analytical development. In addition to manufacturing advancements, Mamta promoted product and platform development for various next-generation TCR-T programs.
Mamta Kalra holds a PhD in Immunology from Post Graduate Institute of Medical Education and Research in India and a postdoctoral training in adoptive T-cell therapy from the Center for Cell and Gene Therapy at Baylor College of Medicine.